Time period |
1990–2040 vs. Levy 2016–2100, to allow some hindcasting, and avoid extrapolation to years where rates very uncertain |
Diseases considered |
Lung cancer (LC), chronic obstructive pulmonary disease (COPD), ischaemic heart disease (IHD) and stroke vs. Levy all causes combined. These form about two thirds of smoking-related mortality (Weitkunat et al. 2015) |
Age range |
10–79 years (30–79 years for estimating mortality) vs. Levy 15–99 years. As death certification unreliable at older years, individuals not considered after age 79. PHIM includes those aged 10–14 years as product use may start then |
Years quit |
Considered only by PHIM, to estimate risk more precisely |
Age of initiation |
To age 35 years vs. Levy to age 25, to reflect US patterns of initiation |
Period over which smoking declines to X |
First 11 years vs. Levy first 10 years. This reflects periods for which TPs estimated in PHIM (1986–1990, 1991–1995 and 1996–2000) |
Former users |
Former users of each product combined, rather than separately. Distinction not relevant as re-initiation disallowed, and PHIM retains full product history |
Relative risks |
Derived from meta-analyses vs. Levy from two CPS studies |
Estimating mortality |
Full product history used, while Levy uses smoking status at the time |